Loading...
Loading...
Bank of America raised its rating on Vitamin Shoppe
VSI from Neutral to Buy and upped its price objective from $65 to $67.
Bank of America noted, "VSI is a rare example of a recession-proof domestic growth story with ample square footage and international potential. Net income is forecast to grow by 25/20/19% from 2012-14 on the back of a 8%/6.5%/6.5% comp and ~9% square footage growth. Importantly, VSI's expected net income growth rate is nearly double that of its hardline peers (~10% per year from 2012-14E) which we believe will help support the company's premium multiple. In addition, with the company debt-free and net cash starting to mount, we believe share repurchases or a dividend could easily be accommodated despite its growth plans."
Vitamin Shoppe closed at $56.35 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in